ECHA Urges Registrants To Weigh Benefits/Risks Of REACH Authorization

When all relevant factors are considered, firms may find that it’s not worth pursuing authorization for a substance of very high concern under REACH, European Chemicals Agency rep Richard Dubourg says. In any case, authorization is only temporary until an appropriate alternative presents itself.